Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. März 2022 07:00 ET | Quelle: Alladapt Immunotherapeutics Inc.

Alladapt Announces Initiation of Encore Open-Label Extension Study for its Harmony Phase 1/2 Study of ADP101 for Treatment of Food Allergy

MENLO PARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
04. Januar 2022 07:00 ET | Quelle: Alladapt Immunotherapeutics Inc.

Alladapt Announces Completion of Patient Enrollment in its Phase 1/2 Harmony Study of ADP101 for Treatment of Food Allergy

MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics to...
19. August 2021 07:00 ET | Quelle: Alladapt Immunotherapeutics Inc.

Alladapt Initiates Buildout of New Manufacturing Facility for Production of Novel, Investigational Oral Immunotherapeutic Designed to Address a Broad Range of Food Allergies

ADP101 is a singular optimized, pharmaceutical-grade oral immunotherapy candidate currently in a Phase 1/2 clinical trial for patients with mono- and multi-food allergies Facility intended to support...
22. Juni 2021 07:00 ET | Quelle: Alladapt Immunotherapeutics Inc.

Alladapt Appoints Glenn Reicin as Chief Financial Officer

MENLO PARK, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics to...

Vorherige Seite